COLCORONA study shows that colchicine can reduce complications in certain COVID-19 patients
The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.
The article, which is entitled Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomized, double-blinded, adaptive, placebo-controlled, multicentre trial, concludes that, given the lack of oral therapies available to prevent COVID-19 complications among non-hospitalized patients and the observed benefit of colchicine in patients with a PCR-confirmed diagnosis of COVID-19, this anti-inflammatory drug could be considered as a treatment for those at risk of complications.
Given the current pandemic, while awaiting collective immunity through vaccination around the world, the need for treatments to prevent COVID-19 complications among patients who contract the disease remains. Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19."